WO2001057081A3 - Nouveaux homologues de type subtilase (narc-1) - Google Patents
Nouveaux homologues de type subtilase (narc-1) Download PDFInfo
- Publication number
- WO2001057081A3 WO2001057081A3 PCT/US2001/003976 US0103976W WO0157081A3 WO 2001057081 A3 WO2001057081 A3 WO 2001057081A3 US 0103976 W US0103976 W US 0103976W WO 0157081 A3 WO0157081 A3 WO 0157081A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotides
- polypeptides
- invention further
- protein
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001241461A AU2001241461A1 (en) | 2000-02-07 | 2001-02-07 | Narc-1, novel subtilase-like homologs |
EP01912710A EP1257572A2 (fr) | 2000-02-07 | 2001-02-07 | Nouveaux homologues de type subtilase (narc-1) |
CA002399727A CA2399727A1 (fr) | 2000-02-07 | 2001-02-07 | Nouveaux homologues de type subtilase (narc-1) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49923500A | 2000-02-07 | 2000-02-07 | |
US09/499,235 | 2000-02-07 | ||
US51790600A | 2000-03-03 | 2000-03-03 | |
US09/517,906 | 2000-03-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001057081A2 WO2001057081A2 (fr) | 2001-08-09 |
WO2001057081A3 true WO2001057081A3 (fr) | 2002-03-14 |
Family
ID=27053087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/003976 WO2001057081A2 (fr) | 2000-02-07 | 2001-02-07 | Nouveaux homologues de type subtilase (narc-1) |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1257572A2 (fr) |
AU (1) | AU2001241461A1 (fr) |
CA (1) | CA2399727A1 (fr) |
WO (1) | WO2001057081A2 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859741B2 (en) | 2007-08-23 | 2014-10-14 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8999341B1 (en) | 2014-07-15 | 2015-04-07 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9062105B1 (en) | 2014-07-15 | 2015-06-23 | Kymab Limited | Precision Medicine by targeting VEGF-A variants for treatment of retinopathy |
US9109034B1 (en) | 2014-07-15 | 2015-08-18 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003106667A2 (fr) * | 2002-06-12 | 2003-12-24 | Bayer Healthcare Ag | Regulation d'une serine protease de type subtilase humaine |
EP1471152A1 (fr) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
EP2444494B1 (fr) | 2006-10-09 | 2016-09-28 | Roche Innovation Center Copenhagen A/S | Composés antagonistes de l'arn pour la modulation de pcsk9 |
JP5588175B2 (ja) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Pcsk9のアンタゴニスト |
CA2680832A1 (fr) | 2007-03-27 | 2008-10-02 | Merck & Co., Inc. | Procede de detection de pcsk9 secretee, autogeneree |
CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
WO2010068526A1 (fr) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Immunodosage de pcsk9 |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
WO2011009697A1 (fr) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Oligomères anti-sens ciblant pcsk9 |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
CN102639150A (zh) | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
AR084938A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
AU2012308797B2 (en) | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
US9540449B2 (en) | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
KR20160024906A (ko) | 2013-06-07 | 2016-03-07 | 사노피 바이오테크놀로지 | Pcsk9의 억제제를 투여함에 의한 죽상경화증의 억제 방법 |
EP3591054A1 (fr) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Oligomères et conjugués antisens ciblant pcsk9 |
EP3882273A1 (fr) | 2013-11-12 | 2021-09-22 | Sanofi Biotechnology | Schémas posologiques pour une utilisation avec des inhibiteurs de pcsk9 |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
GB2521355A (en) * | 2013-12-17 | 2015-06-24 | Kymab Ltd | Human targets I |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR20170029613A (ko) | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
EP3337828A1 (fr) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines |
WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
AU2017382323B2 (en) | 2016-12-23 | 2024-06-13 | President And Fellows Of Harvard College | Gene editing of PCSK9 |
WO2019041066A1 (fr) * | 2017-08-26 | 2019-03-07 | 深圳市博奥康生物科技有限公司 | Construction d'un vecteur d'expression eucaryote fh3 et préparation d'une souche cellulaire à haute expression à l'aide de celui-ci |
WO2021207711A2 (fr) | 2020-04-09 | 2021-10-14 | Verve Therapeutics, Inc. | Arn guides modifiés chimiquement pour l'édition du génome avec cas9 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1067182A2 (fr) * | 1999-07-08 | 2001-01-10 | Helix Research Institute | Proteine secretoire ou proteine de membrane |
WO2001031007A2 (fr) * | 1999-10-22 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee |
-
2001
- 2001-02-07 CA CA002399727A patent/CA2399727A1/fr not_active Abandoned
- 2001-02-07 AU AU2001241461A patent/AU2001241461A1/en not_active Abandoned
- 2001-02-07 WO PCT/US2001/003976 patent/WO2001057081A2/fr not_active Application Discontinuation
- 2001-02-07 EP EP01912710A patent/EP1257572A2/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1067182A2 (fr) * | 1999-07-08 | 2001-01-10 | Helix Research Institute | Proteine secretoire ou proteine de membrane |
WO2001031007A2 (fr) * | 1999-10-22 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee |
Non-Patent Citations (10)
Title |
---|
BARTON A J L ET AL: "Identification of genes differentially expressed between HT-4 clones selected for resistance or sensitivity to glutamate mediated oxidative toxicity.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, 28th Annual Meeting of the Society for Neuroscience, Part 1;Los Angeles, California, USA; November 7-12, 1998, pages 232, XP001027885, ISSN: 0190-5295 * |
CHIANG LILLIAN W ET AL: "An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 5, 27 February 2001 (2001-02-27), February 27, 2001, pages 2814 - 2819, XP002178543, ISSN: 0027-8424 * |
DATABASE EMBL [online] 11 September 1997 (1997-09-11), XP002178545, Database accession no. AA552314 * |
DATABASE EMBL [online] 23 August 1999 (1999-08-23), XP002178546, Database accession no. AI952478 * |
DATABASE EMBL [online] 4 August 1999 (1999-08-04), XP002178544, Database accession no. AI940122 * |
DATABASE EMBL 30 May 2001 (2001-05-30) * |
MILLER TIMOTHY M ET AL: "Metabolic and genetic analyses of apoptosis in potassium/serum-deprived rat cerebellar granule cells.", JOURNAL OF NEUROSCIENCE, vol. 16, no. 23, 1996, pages 7487 - 7495, XP002178541, ISSN: 0270-6474 * |
MUNRO G K L ET AL: "A GENE ENCODING A THERMOPHILIC ALKALINE SERINE PROTEINASE FROM THERMUS SP. STRAIN RT41A AND ITS EXPRESSION IN ESCHERICHIA COLI", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 141, no. PART 7, 1 July 1995 (1995-07-01), pages 1731 - 1738, XP000647015, ISSN: 1350-0872 * |
ROSCHIER MAARIA ET AL: "A differential display protocol to identify differentially expressed mRNAs in potassium-deprived cerebellar granule cells.", BRAIN RESEARCH PROTOCOLS, vol. 5, no. 2, April 2000 (2000-04-01), pages 121 - 131, XP001025685, ISSN: 1385-299X * |
WANG SONGLI ET AL: "Genes induced in programmed cell death of neuronal PC12 cells and developing sympathetic neurons in vivo.", DEVELOPMENTAL BIOLOGY, vol. 188, no. 2, 1997, pages 322 - 336, XP002178542, ISSN: 0012-1606 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859741B2 (en) | 2007-08-23 | 2014-10-14 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8871913B2 (en) | 2007-08-23 | 2014-10-28 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8871914B2 (en) | 2007-08-23 | 2014-10-28 | Amgen, Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8883983B2 (en) | 2007-08-23 | 2014-11-11 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8889834B2 (en) | 2007-08-23 | 2014-11-18 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US9493576B2 (en) | 2007-08-23 | 2016-11-15 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8981064B2 (en) | 2007-08-23 | 2015-03-17 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9109034B1 (en) | 2014-07-15 | 2015-08-18 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8999341B1 (en) | 2014-07-15 | 2015-04-07 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9034331B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9062105B1 (en) | 2014-07-15 | 2015-06-23 | Kymab Limited | Precision Medicine by targeting VEGF-A variants for treatment of retinopathy |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
US9187562B1 (en) | 2014-07-15 | 2015-11-17 | Kymab Limited | Methods for treating anaemia |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9303089B2 (en) | 2014-07-15 | 2016-04-05 | Kymab Limited | Methods of treating anaemia |
US9394568B2 (en) | 2014-07-15 | 2016-07-19 | Kymab Limited | Methods of treating anaemia |
US9428578B2 (en) | 2014-07-15 | 2016-08-30 | Kymab Limited | Methods of treating anaemia |
US9439963B2 (en) | 2014-07-15 | 2016-09-13 | Kymab Limited | Methods of treating anaemia |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
Also Published As
Publication number | Publication date |
---|---|
AU2001241461A1 (en) | 2001-08-14 |
WO2001057081A2 (fr) | 2001-08-09 |
EP1257572A2 (fr) | 2002-11-20 |
CA2399727A1 (fr) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001057081A3 (fr) | Nouveaux homologues de type subtilase (narc-1) | |
AU5608000A (en) | 22025, a novel human cyclic nucleotide phosphodiesterase | |
WO2001032891A3 (fr) | 188891, nouvelle lipase humaine | |
WO2002086076A3 (fr) | Polynucleotides et polypeptides associes au chemin nf-kb | |
WO2002072751A3 (fr) | Polynucleotides codant une nouvelle metalloprotease, mp-1 | |
WO2004100886A3 (fr) | Polynucleotides et polypeptides associes a la voie nf-kb | |
WO2002018576A3 (fr) | Compositions et methodes associees aux genes specifiques du poumon | |
WO2001000811A8 (fr) | Nouvelle aminopeptidase humaine (17867) | |
WO2001036605A3 (fr) | 2786, nouvelle aminopeptidase humaine | |
WO2003027231A3 (fr) | Polynucleotide codant pour une nouvelle proteine d'adaptation, pmn29, contenant le domaine d'homologie avec la pleckstrine et le domaine riche en proline | |
WO2001023590A3 (fr) | La 22196, nouvelle aminopeptidase humaine | |
WO2001023589A3 (fr) | Nouvelle ubiquitine protease humaine nommee 23431 | |
WO2001064858A3 (fr) | 25312, un nouvel homologue humain du type agmatinase | |
WO2001064880A3 (fr) | La 40322, nouvelle dynamine humaine | |
WO2001000812A3 (fr) | 22012, une nouvelle carboxypeptidase humaine | |
WO2001044446A3 (fr) | Nouveaux alcools-deshydrogenases 21612, 21615, 21620, 21676, 33756 | |
ATE348889T1 (de) | 27411, eine menschliche phosphatidyl- glycerinphosphate (pgp) synthase | |
EP0812916A3 (fr) | Gène de la cathepsin K | |
WO2001064887A3 (fr) | Nouvelles protéines g humaines 32705, 23224, 27423, 32700, 32712 | |
WO1999030670A3 (fr) | Procedes de traitement utilisant de nouveaux ligands du recepteur hfgan72 de neuropeptides et leurs agonistes ou antagonistes | |
WO2001064873A3 (fr) | Nouvelles proteines activatrices de gtpase humaines | |
WO2001059081A3 (fr) | Procedes d'utilisation de 20893, une proteine kinase humaine | |
WO2002008278A3 (fr) | Compositions et procedes relatifs aux genes specifiques aux poumons | |
IL155687A0 (en) | Polynucleotides encoding hlrrsi1 polypeptides | |
WO2002000826A3 (fr) | Nouveau polypeptide, proteine humaine de methylation d'adn, et polynucleotide codant ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2399727 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 557912 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001912710 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001912710 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001912710 Country of ref document: EP |